Recently, two papers have been published showing that testosterone has been identified as a novel crucial factor for immunotherapy in prostate and bladder carcinoma by directly diminishing CD8+ T cell function via the androgen receptor [57,58]. This evidence concerns the gene AR and urinary bladder carcinoma.